CA2295474A1 - 123 human secreted proteins - Google Patents
123 human secreted proteins Download PDFInfo
- Publication number
- CA2295474A1 CA2295474A1 CA002295474A CA2295474A CA2295474A1 CA 2295474 A1 CA2295474 A1 CA 2295474A1 CA 002295474 A CA002295474 A CA 002295474A CA 2295474 A CA2295474 A CA 2295474A CA 2295474 A1 CA2295474 A1 CA 2295474A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- gene
- tissues
- polynucleotides
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 723
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 255
- 241000282414 Homo sapiens Species 0.000 title abstract description 37
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 16
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 13
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 13
- 239000013598 vector Substances 0.000 claims abstract description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 402
- 108091033319 polynucleotide Proteins 0.000 claims description 402
- 239000002157 polynucleotide Substances 0.000 claims description 401
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 358
- 229920001184 polypeptide Polymers 0.000 claims description 356
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 356
- 230000014509 gene expression Effects 0.000 claims description 234
- 125000003729 nucleotide group Chemical group 0.000 claims description 156
- 239000000047 product Substances 0.000 claims description 122
- 239000002773 nucleotide Substances 0.000 claims description 86
- 239000012472 biological sample Substances 0.000 claims description 70
- 239000012634 fragment Substances 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 32
- 239000002299 complementary DNA Substances 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 7
- 230000004071 biological effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000004166 bioassay Methods 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims 8
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 abstract description 2
- 238000002405 diagnostic procedure Methods 0.000 abstract description 2
- 238000010188 recombinant method Methods 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 736
- 210000004027 cell Anatomy 0.000 description 386
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 365
- 208000035475 disorder Diseases 0.000 description 276
- 235000018102 proteins Nutrition 0.000 description 245
- 239000000523 sample Substances 0.000 description 146
- 210000001124 body fluid Anatomy 0.000 description 133
- 238000003745 diagnosis Methods 0.000 description 112
- 201000010099 disease Diseases 0.000 description 88
- 206010028980 Neoplasm Diseases 0.000 description 82
- 238000011282 treatment Methods 0.000 description 79
- 239000003153 chemical reaction reagent Substances 0.000 description 73
- 238000009826 distribution Methods 0.000 description 72
- 239000012530 fluid Substances 0.000 description 71
- 210000001179 synovial fluid Anatomy 0.000 description 69
- 210000002700 urine Anatomy 0.000 description 69
- 210000002381 plasma Anatomy 0.000 description 68
- 210000002966 serum Anatomy 0.000 description 68
- 230000001900 immune effect Effects 0.000 description 67
- 238000009169 immunotherapy Methods 0.000 description 62
- 239000000439 tumor marker Substances 0.000 description 52
- 208000026278 immune system disease Diseases 0.000 description 48
- 230000035755 proliferation Effects 0.000 description 48
- 230000004069 differentiation Effects 0.000 description 46
- 210000000130 stem cell Anatomy 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 37
- 239000008280 blood Substances 0.000 description 37
- 238000001514 detection method Methods 0.000 description 33
- 230000004913 activation Effects 0.000 description 30
- 201000011510 cancer Diseases 0.000 description 30
- 210000000987 immune system Anatomy 0.000 description 30
- 210000001744 T-lymphocyte Anatomy 0.000 description 28
- 210000002751 lymph Anatomy 0.000 description 26
- 230000033228 biological regulation Effects 0.000 description 24
- 206010003246 arthritis Diseases 0.000 description 22
- 230000037361 pathway Effects 0.000 description 22
- 230000014616 translation Effects 0.000 description 22
- 238000013519 translation Methods 0.000 description 22
- 208000032839 leukemia Diseases 0.000 description 21
- 230000008569 process Effects 0.000 description 21
- 208000006673 asthma Diseases 0.000 description 20
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 20
- 210000002865 immune cell Anatomy 0.000 description 19
- 230000001850 reproductive effect Effects 0.000 description 19
- 208000030507 AIDS Diseases 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 18
- 208000003669 immune deficiency disease Diseases 0.000 description 18
- 230000036737 immune function Effects 0.000 description 18
- 239000003550 marker Substances 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 18
- 206010061535 Ovarian neoplasm Diseases 0.000 description 17
- 230000030741 antigen processing and presentation Effects 0.000 description 17
- 230000028993 immune response Effects 0.000 description 17
- 230000024833 regulation of cytokine production Effects 0.000 description 17
- 210000000349 chromosome Anatomy 0.000 description 16
- 208000015122 neurodegenerative disease Diseases 0.000 description 15
- 206010000117 Abnormal behaviour Diseases 0.000 description 14
- 208000024827 Alzheimer disease Diseases 0.000 description 14
- 206010033128 Ovarian cancer Diseases 0.000 description 14
- 230000004770 neurodegeneration Effects 0.000 description 14
- 210000004994 reproductive system Anatomy 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 206010012289 Dementia Diseases 0.000 description 13
- 208000012239 Developmental disease Diseases 0.000 description 13
- 208000023105 Huntington disease Diseases 0.000 description 13
- 206010026749 Mania Diseases 0.000 description 13
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 13
- 206010033864 Paranoia Diseases 0.000 description 13
- 208000027099 Paranoid disease Diseases 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 13
- 230000001605 fetal effect Effects 0.000 description 13
- 210000000440 neutrophil Anatomy 0.000 description 13
- 208000019906 panic disease Diseases 0.000 description 13
- 201000000980 schizophrenia Diseases 0.000 description 13
- 206010003805 Autism Diseases 0.000 description 12
- 208000020706 Autistic disease Diseases 0.000 description 12
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 12
- 208000018737 Parkinson disease Diseases 0.000 description 12
- 208000028017 Psychotic disease Diseases 0.000 description 12
- 208000000323 Tourette Syndrome Diseases 0.000 description 12
- 208000016620 Tourette disease Diseases 0.000 description 12
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 12
- 210000001185 bone marrow Anatomy 0.000 description 12
- 210000000748 cardiovascular system Anatomy 0.000 description 12
- 210000003169 central nervous system Anatomy 0.000 description 12
- 201000003723 learning disability Diseases 0.000 description 12
- 210000001161 mammalian embryo Anatomy 0.000 description 12
- 230000007958 sleep Effects 0.000 description 12
- 206010020751 Hypersensitivity Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000019491 signal transduction Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000001537 neural effect Effects 0.000 description 9
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 208000029462 Immunodeficiency disease Diseases 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 230000007815 allergy Effects 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 210000004381 amniotic fluid Anatomy 0.000 description 8
- 210000000601 blood cell Anatomy 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 210000001550 testis Anatomy 0.000 description 8
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 230000002124 endocrine Effects 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 210000001723 extracellular space Anatomy 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000003061 neural cell Anatomy 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 206010061598 Immunodeficiency Diseases 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 6
- 230000007813 immunodeficiency Effects 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000000653 nervous system Anatomy 0.000 description 6
- 210000003463 organelle Anatomy 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 208000017701 Endocrine disease Diseases 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 101000693908 Pisum sativum Secretory carrier-associated membrane protein Proteins 0.000 description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 210000002798 bone marrow cell Anatomy 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000002741 palatine tonsil Anatomy 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 206010046766 uterine cancer Diseases 0.000 description 5
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- 208000008383 Wilms tumor Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000001638 cerebellum Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 230000028023 exocytosis Effects 0.000 description 4
- 210000004996 female reproductive system Anatomy 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 210000004739 secretory vesicle Anatomy 0.000 description 4
- 210000001258 synovial membrane Anatomy 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000009547 development abnormality Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 208000003532 hypothyroidism Diseases 0.000 description 3
- 230000002989 hypothyroidism Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002583 male contraceptive agent Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000007261 regionalization Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000005227 renal system Anatomy 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000002381 testicular Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 206010001367 Adrenal insufficiency Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100034582 E3 ubiquitin/ISG15 ligase TRIM25 Human genes 0.000 description 2
- 101710183057 E3 ubiquitin/ISG15 ligase TRIM25 Proteins 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 208000023661 Haematological disease Diseases 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 101100364975 Homo sapiens SCAMP1 gene Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000321461 Mycteroperca phenax Species 0.000 description 2
- 102400000058 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 206010033661 Pancytopenia Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 101150040459 RAS gene Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100037230 Secretory carrier-associated membrane protein 1 Human genes 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 208000000491 Tendinopathy Diseases 0.000 description 2
- 206010043255 Tendonitis Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 102000009764 Uroplakin III Human genes 0.000 description 2
- 108010009737 Uroplakin III Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 208000030270 breast disease Diseases 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000011124 ex vivo culture Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 210000002504 synaptic vesicle Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 201000004415 tendinitis Diseases 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100002951 Caenorhabditis elegans asp-17 gene Proteins 0.000 description 1
- 101100338269 Caenorhabditis elegans his-41 gene Proteins 0.000 description 1
- 101100177114 Caenorhabditis elegans his-69 gene Proteins 0.000 description 1
- 101100289894 Caenorhabditis elegans lys-7 gene Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000012545 EGF-like domains Human genes 0.000 description 1
- 108050002150 EGF-like domains Proteins 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010061857 Fat necrosis Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000590687 Homo sapiens U3 small nucleolar ribonucleoprotein protein MPP10 Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- -1 I50 amino acids Chemical class 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010075645 MAP Kinase Kinase Kinase 3 Proteins 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100033059 Mitogen-activated protein kinase kinase kinase 3 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000931108 Mus musculus DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 101100449929 Mus musculus Guca1a gene Proteins 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 206010065673 Nephritic syndrome Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 101710191627 Photosystem II CP43 reaction center protein Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 1
- 101710132808 Protein P6 Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000025609 Urogenital disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000017504 atelosteogenesis type II Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000017568 chondrodysplasia Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000001613 integumentary system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000015625 metaphyseal chondrodysplasia Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 201000003504 spondyloepiphyseal dysplasia congenita Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (65)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5279597P | 1997-07-08 | 1997-07-08 | |
| US5193197P | 1997-07-08 | 1997-07-08 | |
| US5192997P | 1997-07-08 | 1997-07-08 | |
| US5192597P | 1997-07-08 | 1997-07-08 | |
| US5280397P | 1997-07-08 | 1997-07-08 | |
| US5192897P | 1997-07-08 | 1997-07-08 | |
| US5279397P | 1997-07-08 | 1997-07-08 | |
| US5191897P | 1997-07-08 | 1997-07-08 | |
| US5273397P | 1997-07-08 | 1997-07-08 | |
| US5192697P | 1997-07-08 | 1997-07-08 | |
| US5191697P | 1997-07-08 | 1997-07-08 | |
| US5193097P | 1997-07-08 | 1997-07-08 | |
| US5192097P | 1997-07-08 | 1997-07-08 | |
| US5193297P | 1997-07-08 | 1997-07-08 | |
| US5273297P | 1997-07-08 | 1997-07-08 | |
| US5191997P | 1997-07-08 | 1997-07-08 | |
| US60/051,918 | 1997-07-08 | ||
| US60/052,793 | 1997-07-08 | ||
| US60/052,803 | 1997-07-08 | ||
| US60/051,916 | 1997-07-08 | ||
| US60/051,932 | 1997-07-08 | ||
| US60/051,928 | 1997-07-08 | ||
| US60/051,929 | 1997-07-08 | ||
| US60/051,930 | 1997-07-08 | ||
| US60/052,732 | 1997-07-08 | ||
| US60/051,931 | 1997-07-08 | ||
| US60/051,926 | 1997-07-08 | ||
| US60/052,795 | 1997-07-08 | ||
| US60/051,920 | 1997-07-08 | ||
| US60/052,733 | 1997-07-08 | ||
| US60/051,925 | 1997-07-08 | ||
| US5594797P | 1997-08-18 | 1997-08-18 | |
| US5595097P | 1997-08-18 | 1997-08-18 | |
| US5572297P | 1997-08-18 | 1997-08-18 | |
| US5636097P | 1997-08-18 | 1997-08-18 | |
| US5595397P | 1997-08-18 | 1997-08-18 | |
| US5594997P | 1997-08-18 | 1997-08-18 | |
| US5595497P | 1997-08-18 | 1997-08-18 | |
| US5594897P | 1997-08-18 | 1997-08-18 | |
| US5568497P | 1997-08-18 | 1997-08-18 | |
| US5572397P | 1997-08-18 | 1997-08-18 | |
| US5596497P | 1997-08-18 | 1997-08-18 | |
| US5598497P | 1997-08-18 | 1997-08-18 | |
| US60/055,723 | 1997-08-18 | ||
| US60/056,360 | 1997-08-18 | ||
| US60/055,948 | 1997-08-18 | ||
| US60/055,950 | 1997-08-18 | ||
| US60/055,964 | 1997-08-18 | ||
| US60/055,954 | 1997-08-18 | ||
| US60/055,722 | 1997-08-18 | ||
| US60/055,684 | 1997-08-18 | ||
| US60/055,953 | 1997-08-18 | ||
| US60/055,949 | 1997-08-18 | ||
| US60/055,947 | 1997-08-18 | ||
| US5866497P | 1997-09-12 | 1997-09-12 | |
| US5866097P | 1997-09-12 | 1997-09-12 | |
| US5866197P | 1997-09-12 | 1997-09-12 | |
| US5878597P | 1997-09-12 | 1997-09-12 | |
| US60/058,785 | 1997-09-12 | ||
| US60/058,660 | 1997-09-12 | ||
| US60/058,664 | 1997-09-12 | ||
| US60/058,661 | 1997-09-12 | ||
| US60/051,919 | 1997-10-02 | ||
| US60/055,984 | 1997-10-02 | ||
| PCT/US1998/013684 WO1999002546A1 (en) | 1997-07-08 | 1998-07-07 | 123 human secreted proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2295474A1 true CA2295474A1 (en) | 1999-01-21 |
Family
ID=27586903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002295474A Abandoned CA2295474A1 (en) | 1997-07-08 | 1998-07-07 | 123 human secreted proteins |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US6342581B1 (enExample) |
| EP (1) | EP1000084A4 (enExample) |
| JP (1) | JP2002513295A (enExample) |
| CA (1) | CA2295474A1 (enExample) |
| WO (1) | WO1999002546A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002546A1 (en) | 1997-07-08 | 1999-01-21 | Human Genome Sciences, Inc. | 123 human secreted proteins |
| WO2000047602A1 (en) * | 1999-02-10 | 2000-08-17 | Human Genome Sciences, Inc. | 33 human secreted proteins |
| PT1003861E (pt) * | 1997-08-01 | 2007-01-31 | Schering Corp | Proteínas de membrana de células de mamíferos;reagentes relacionados |
| EP0949332A3 (en) * | 1998-04-01 | 2001-03-28 | Smithkline Beecham Plc | HSSCRG1 polypeptides |
| WO1999060124A2 (en) * | 1998-05-15 | 1999-11-25 | Fei Huang | Differentiation-associated sequences and methods of use therefor |
| US6753154B1 (en) * | 1998-06-26 | 2004-06-22 | The Regents Of The University Of California | Human AZU-1 gene, variants thereof and expressed gene products |
| EP1114153A2 (en) * | 1998-09-18 | 2001-07-11 | The Rockefeller University | Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof |
| BR9914465A (pt) * | 1998-09-29 | 2001-10-09 | Gamida Cell Ltd | Métodos para controlar a proliferação e a diferenciação de células-tronco e células progenitoras e uma composição farmacêutica para induzir a diferenciação em uma população de células |
| US6544946B1 (en) | 1999-02-19 | 2003-04-08 | Zymogenetics, Inc. | Inhibitors for use in hemostasis and immune function |
| EP1382345A3 (en) | 1999-02-19 | 2004-01-28 | Zymogenetics Inc | Uses of inhibitors of hemostasis |
| EP1181037A4 (en) * | 1999-05-01 | 2006-01-18 | Genaera Corp | FACTORS ASSOCIATED WITH ASTHMA AS TARGETS FOR TREATING ATOPIC ALLERGIES, ESPECIALLY ASTHMA AND RELATED DISORDERS |
| WO2000073448A1 (en) * | 1999-05-27 | 2000-12-07 | Zymogenetics, Inc. | Adipocyte complement related protein homolog zacrp7 |
| CA2377263A1 (en) * | 1999-06-23 | 2000-12-28 | Curagen Corporation | Polynucleotides and polypeptides encoded thereby |
| AU1392801A (en) * | 1999-11-10 | 2001-06-06 | Smithkline Beecham Biologicals (Sa) | Casb7434, an antigen over-expressed in colon cancer |
| EP1239035A4 (en) * | 1999-12-17 | 2005-04-06 | Mitsubishi Pharma Corp | PROTEIN AND GEN |
| WO2001068806A2 (en) * | 2000-03-10 | 2001-09-20 | Millennium Pharmaceuticals, Inc. | 26934, a novel cytidine deaminase-like molecule and uses thereof |
| US20030096315A1 (en) | 2000-05-03 | 2003-05-22 | Sanders Mitchell C. | Device for detecting bacterial contamination and method of use |
| US20020111302A1 (en) * | 2000-11-30 | 2002-08-15 | Y. Tom Tang | Novel nucleic acids and polypeptides |
| WO2002080852A2 (en) * | 2001-04-04 | 2002-10-17 | Digital Gene Technologies, Inc. | Genes expressed in intestinal epithelium and peyer's patch m cells |
| IL152904A0 (en) * | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
| WO2003062404A1 (en) * | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
| EP1576181B1 (en) * | 2002-01-31 | 2013-08-14 | Systagenix Wound Management IP Co. BV. | Method for detecting pathogenic bacteria in wounds |
| WO2003074546A2 (de) * | 2002-03-01 | 2003-09-12 | Erdmann Volker A | Streptavidin-bindungspeptid |
| GB0208925D0 (en) * | 2002-04-12 | 2002-05-29 | Univ Sheffield | Polypeptide |
| EP1557466B1 (en) * | 2002-09-27 | 2009-09-02 | Dainippon Sumitomo Pharma Co., Ltd. | Tumor antigen protein and utilization thereof |
| ATE440284T1 (de) * | 2003-01-09 | 2009-09-15 | Beth Israel Hospital | Verwendung von adiponectin zur diagnose von krebs |
| AU2004225575B2 (en) * | 2003-01-31 | 2008-02-21 | Ethicon, Inc. | Method for detecting escherichia coli |
| WO2004072268A2 (en) * | 2003-02-12 | 2004-08-26 | Mayo Foundation For Medical Education And Research | Pkhdl1, a homolog of the autosomal recessive kidney disease gene |
| US7312197B2 (en) * | 2003-02-24 | 2007-12-25 | University Of Maryland, Baltimore | Method of modifying glucose activity using polypeptides selectively expressed in fat tissue |
| US20050075543A1 (en) * | 2003-10-03 | 2005-04-07 | Calabrese Charles A. | Method of anonymous medical testing and providing the patient with the test results |
| JP4864715B2 (ja) | 2003-11-03 | 2012-02-01 | エチコン・インコーポレーテツド | 細菌の広域スペクトルの検出に有用な方法、ペプチドおよびバイオセンサー |
| US20070210713A1 (en) * | 2004-04-08 | 2007-09-13 | Sen Engineering Co., Ltd. | Dielectric Barrier Discharge Excimer Light Source |
| WO2006030442A2 (en) * | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
| JP5041231B2 (ja) * | 2005-02-15 | 2012-10-03 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
| US8058014B2 (en) * | 2006-09-29 | 2011-11-15 | University Of Maryland, Baltimore | Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2 |
| BRPI0720219A2 (pt) | 2006-12-08 | 2013-12-24 | Univ Iowa State Res Found Inc | Genes de planta envolvidos em absorção e metabolismo de nitrato |
| RU2607569C2 (ru) * | 2008-03-31 | 2017-01-10 | Дженентек, Инк. | Композиции и способы для лечения и диагностики астмы |
| US8082730B2 (en) * | 2008-05-20 | 2011-12-27 | Caterpillar Inc. | Engine system having particulate reduction device and method |
| US9260499B2 (en) | 2008-10-20 | 2016-02-16 | Sapporo Medical University | Tumor antigen peptide and use thereof |
| KR101615474B1 (ko) | 2010-12-16 | 2016-04-25 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| EP2714096B1 (en) | 2011-06-03 | 2018-02-28 | Ophidion Inc. | Compositions and methods for transport across the blood brain barrier |
| JP6348848B2 (ja) | 2012-02-13 | 2018-06-27 | ガミダ セル リミテッド | 間葉系幹細胞の増殖 |
| US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
| US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
| EP2970884A4 (en) | 2013-03-14 | 2016-11-02 | Univ Florida | DI-AMINO ACID-REINFORCED PROTEINS ASSOCIATED WITH ALS |
| WO2016196324A1 (en) | 2015-05-29 | 2016-12-08 | University Of Floridia Research Foundation, Inc. | Methods for diagnosing huntington's disease |
| US10940161B2 (en) | 2016-04-04 | 2021-03-09 | University Of Florida Research Foundation, Incorporated | Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation |
| MX389549B (es) * | 2016-04-06 | 2025-03-20 | Plant Health Care Inc | Peptidos derivados de inductores de respuesta de hipersensibilidad y su uso. |
| JP7526455B2 (ja) | 2017-04-17 | 2024-08-01 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | ＰＫＲおよびｅＩＦ２Ａ－Ｐ経路によるＲＡＮタンパク質翻訳の調節 |
| CN110753555A (zh) | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| JP7350337B2 (ja) | 2017-09-26 | 2023-09-26 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用 |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| JP7620988B2 (ja) | 2019-09-20 | 2025-01-24 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 血清および組織ライセートからのｒａｎタンパク質に対する抗体の検出 |
| CN114349826B (zh) * | 2022-02-14 | 2023-05-30 | 山东省科学院生物研究所 | 抗菌肽cgs7及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580753A (en) * | 1989-05-23 | 1996-12-03 | Ludwig Institute For Cancer Research | DNA encoding the human cytokine, interleukin-9 |
| NZ301067A (en) * | 1994-12-06 | 1998-03-25 | Immunex Corp | Cytokine designated lerk-7 for activating tyrosine kinases |
| US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| WO1999002546A1 (en) | 1997-07-08 | 1999-01-21 | Human Genome Sciences, Inc. | 123 human secreted proteins |
| DE19733389C2 (de) | 1997-08-01 | 1999-08-19 | Deutsches Krebsforsch | Mittel zur Expression und zum Nachweis eines ein HPOL-Epitop und ein Polypeptid enthaltenden Fusionspolypeptids |
| DE69835751T2 (de) | 1997-08-01 | 2007-10-04 | Serono Genetics Institute S.A. | 5' ests für proteine, die nicht gewebespezifisch sind |
| US6416973B1 (en) | 1997-08-01 | 2002-07-09 | Schering Corporation | Nucleic acids encoding mammalian cell membrane protein MDL-1 |
| EP1114153A2 (en) | 1998-09-18 | 2001-07-11 | The Rockefeller University | Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof |
| EP1414845A4 (en) | 2001-03-21 | 2009-07-08 | Human Genome Sciences | SEPARATE HUMAN PROTEINS |
-
1998
- 1998-07-07 WO PCT/US1998/013684 patent/WO1999002546A1/en not_active Ceased
- 1998-07-07 JP JP50874499A patent/JP2002513295A/ja not_active Withdrawn
- 1998-07-07 EP EP98935509A patent/EP1000084A4/en not_active Withdrawn
- 1998-07-07 CA CA002295474A patent/CA2295474A1/en not_active Abandoned
-
1999
- 1999-01-08 US US09/227,357 patent/US6342581B1/en not_active Expired - Fee Related
-
2001
- 2001-10-25 US US09/983,802 patent/US7105644B2/en not_active Expired - Fee Related
- 2001-10-30 US US09/984,490 patent/US20030064412A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20030022185A1 (en) | 2003-01-30 |
| EP1000084A4 (en) | 2003-03-26 |
| JP2002513295A (ja) | 2002-05-08 |
| WO1999002546A1 (en) | 1999-01-21 |
| US6342581B1 (en) | 2002-01-29 |
| US7105644B2 (en) | 2006-09-12 |
| EP1000084A1 (en) | 2000-05-17 |
| US20030064412A1 (en) | 2003-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7105644B2 (en) | Secreted protein HHTLF25 antibodies | |
| US20050089911A1 (en) | 87 human secreted proteins | |
| US20030225248A1 (en) | 186 human secreted proteins | |
| EP1040117A1 (en) | 110 human secreted proteins | |
| US6525174B1 (en) | Precerebellin-like protein | |
| WO1999038881A1 (en) | 67 human secreted proteins | |
| US20050095612A1 (en) | 70 human secreted proteins | |
| CA2291221A1 (en) | 32 human secreted proteins | |
| WO1999047540A1 (en) | 95 human secreted proteins | |
| CA2294526A1 (en) | 86 human secreted proteins | |
| EP1044211A1 (en) | 36 human secreted proteins | |
| EP1019091A1 (en) | 50 human secreted proteins | |
| US7053190B2 (en) | Secreted protein HRGDF73 | |
| WO1999003990A1 (en) | 64 human secreted proteins | |
| WO1999024836A1 (en) | 125 human secreted proteins | |
| US20060188962A1 (en) | 19 human secreted proteins | |
| CA2305690A1 (en) | 53 human secreted proteins | |
| WO1999022243A1 (en) | 148 human secreted proteins | |
| CA2298852A1 (en) | 83 human secreted proteins | |
| WO1999010363A1 (en) | 29 human secreted proteins | |
| US20050214844A1 (en) | 86 human secreted proteins | |
| US20070238664A1 (en) | 70 Human Secreted Proteins | |
| EP1557425A2 (en) | 123 human secreted proteins | |
| EP1439189A2 (en) | 86 Human Secreted Proteins | |
| EP1346999A2 (en) | Human secreted protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |